A Randomised, Double-blind, Placebo-controlled Phase 1 Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SLN124 in Healthy Volunteers.
Latest Information Update: 24 Apr 2023
At a glance
- Drugs Divesiran (Primary)
- Indications Beta-thalassaemia; Myelodysplastic syndromes; Polycythaemia vera
- Focus Adverse reactions; First in man
- Acronyms GEMINI
- Sponsors Silence Therapeutics
- 08 Sep 2022 Status changed from active, no longer recruiting to completed, according to a Silence Therapeutics media release.
- 12 Dec 2021 Results published in the Silence Therapeutics Media Release.
- 12 Dec 2021 According to a Silence Therapeutics media release, additional positive data from the study was presented at the 2021 American Society of Hematology (ASH) Annual Meeting.